Annales françaises de médecine d'urgence

, Volume 3, Issue 3, pp 138–144

Évaluation de la copeptine dans les syndromes coronaires aigus non ST+

  • S. Ledochowski
  • J.-M. Fayet
  • D. Collin-Chavagnac
  • E. Bonnefoy-Cudraz
Article Original / Original Article
  • 172 Downloads

Résumé

Introduction

Une méthode fiable et rapide d’exclusion de l’infarctus du myocarde (IDM) représente un objectif médical crucial à atteindre. Une des pistes de la recherche actuelle est d’associer des marqueurs indépendants de la physiopathologie ischémique pour améliorer le diagnostic d’IDM.

Matériel et méthodes

Notre étude, observationnelle, rétrospective et monocentrique, a été réalisée sur une population de patients se présentant au service d’accueil des urgences du centre hospitalier Lyon-Sud pour une douleur thoracique apparue dans les six heures précédentes. Quatre-vingt-trois patients ont été inclus d’âge moyen de 64 ans dont neuf cas d’infarctus non ST+. Son objectif principal a été de déterminer la performance statistique de la copeptine dans l’exclusion des syndromes coronariens sans élévation du segment ST (SCA NST+). L’objectif secondaire a été d’estimer le gain de temps potentiel d’un schéma décisionnel utilisant le couple copeptine-première troponine par rapport au schéma classique double dosage de la troponine dans l’exclusion de l’IDM.

Résultats

Notre évaluation d’une stratégie double, associant copeptine et le premier dosage de troponine avec un cut-off de 9 pmol/l, retrouve un rapport de vraisemblance négatif proche de 0,0 (0,01–1,92), une sensibilité à 1,0 (IC 95 %: 0,66–1), une valeur prédictive négative à 1,0 (IC 95 %: 0,88–1) et un taux d’erreurs semblant être inférieur à 10 %. Le gain de temps potentiel en utilisant une stratégie double est de 310 minutes, soit un peu plus de cinq heures.

Conclusion

L’association de la copeptine améliore significativement la valeur diagnostique de la troponine pour l’exclusion des SCA NST+ aux urgences, tout en permettant au clinicien de réduire les délais de prise en charge.

Mots clés

Syndrome coronarien aigu Non ST+ Copeptine Troponine Sensibilité Spécificité 

Evaluation for copeptin in NSTEMIs

Abstract

Introduction

A reliable and rapid method to exclude acute myocardial infarction (AMI) is a crucial medical objective to achieve. One area of current research is to use pathophysiological markers of independent dimensions to improve the diagnosis of AMI.

Material and methods

Our study, observational, retrospective and single-centered, was performed on a population of patients consulting to the Emergency Ward of the University Hospital of Lyon Sud for a chest pain that occurred within 6 hours. Its main objective was to determine the statistical performance of copeptin in non-ST elevated myocardial infarction (NSTEMI)-exclusion. Eighty-three patients were included with a mean age of 64 and with 9 patients diagnosed with NSTEMI. The secondary objective was to estimate the potential time savings of a decision tree using copeptin associated with the first troponin compared with the conventional double-troponin in the exclusion of MI.

Results

Our evaluation of a dual strategy, combining copeptin and the first troponin with a cutoff of 9 pmol/l, found a negative likelihood ratio close to 0.0 (0.01–1.92), a sensitivity close to 1.0 (95% CI: 0.66–1), a negative predictive value close to 1.0 (95%: 0.88–1) with an error rate of less than 10%. The time-saving potential of the decision tree using a dual strategy is estimated to be 310 min, or just over 5 hours.

Conclusion

The combination of troponin and copeptin significantly improves the diagnostic value of troponin for the exclusion of NSTEMI, while allowing the clinician to reduce delays in care.

Keywords

NSTEMI Copeptin Troponin Sensitivity Specificity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Nawar EW, Niska RW, Xu J (2007) National Hospital Ambulatory Medical Care Survey: 2005 emergency department summary. Adv Data 386:1–32PubMedGoogle Scholar
  2. 2.
    Thygesen K, Alpert JS, White HD, et al (2007) Universal definition of myocardial infarction. Circulation 16:2634–53CrossRefGoogle Scholar
  3. 3.
    Macrae AR, Kavsak PA, Lustig V, et al (2006) Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. Clin Chem 52:812–8PubMedCrossRefGoogle Scholar
  4. 4.
    National Heart Attack Alert Program Coordinating Committee, 60 Minutes to Treatment Working Group (1994) Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 23:311–29CrossRefGoogle Scholar
  5. 5.
    Wu AHB, Jaffe AS (2008) The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J 155:208–14PubMedCrossRefGoogle Scholar
  6. 6.
    Keller T, Münzel T, Blankenberg S (2011) Making it more sensitive. Circulation 123:1361–3PubMedCrossRefGoogle Scholar
  7. 7.
    Jochberger S, Mayr VD, Luckner G, et al (2006) Serum vasopressin concentrations in critically ill patients. Crit Care Med 34:293–9PubMedCrossRefGoogle Scholar
  8. 8.
    Khan SQ, Dhillon OS, O’Brien RJ, et al (2007) C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115:2103–10PubMedCrossRefGoogle Scholar
  9. 9.
    Morgenthaler NG, Struck J, Alonso C, et al (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–9PubMedCrossRefGoogle Scholar
  10. 10.
    Reichlin T, Hochholzer W, Stelzig C, et al (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54:60–8PubMedCrossRefGoogle Scholar
  11. 11.
    Keller T, Tzikas S, Zeller T, et al (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–106PubMedCrossRefGoogle Scholar
  12. 12.
    Wright RS, Anderson JL, Adams CD, et al (2011) ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician. Circulation 123:2022–60PubMedCrossRefGoogle Scholar
  13. 13.
    Bossuyt PM, Reitsma JB, Bruns DE, et al (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. The Standards for Reporting of Diagnostic Accuracy Group. Clin Chem 49:1–6PubMedCrossRefGoogle Scholar
  14. 14.
    Keller T, Zeller T, Peetz D, et al (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868–77PubMedCrossRefGoogle Scholar
  15. 15.
    Giannitsis E, Kehayova T, Vafaie M, et al (2011) Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cut-offs improves rapid rule-out of non-ST-segment elevation myocardial infarction. Clin Chem 57:1452–5PubMedCrossRefGoogle Scholar
  16. 16.
    Tate JR (2008) Troponin revisited 2008: assay performance. Clin Chem Lab Med 46:1489–500PubMedCrossRefGoogle Scholar
  17. 17.
    Collinson PO, Heung YM, Gaze D, et al (2012) Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 58:219–25PubMedCrossRefGoogle Scholar
  18. 18.
    Ray P, Le Manach Y, Riou B, et al (2010) Statistical evaluation of a biomarker. Anesthesiology 112:1023–40PubMedCrossRefGoogle Scholar
  19. 19.
    Baker M (2005) In biomarkers we trust? Nat Biotech 23:297–304CrossRefGoogle Scholar
  20. 20.
    Deeks JJ (2001) Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 323:157–62PubMedCrossRefGoogle Scholar
  21. 21.
    De Meyer G, Shapiro F (2003) Biomarker development: the road to clinical utility. Curr Drug Discov 12:23–7Google Scholar
  22. 22.
    Miller WL, Hartman KA, Grill DE, et al (2012). Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 98:389–94PubMedCrossRefGoogle Scholar
  23. 23.
    Katan M, Fluri F, Morgenthaler NG, et al (2009) Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 66:799–808PubMedCrossRefGoogle Scholar
  24. 24.
    Müller B, Morgenthaler N, Stolz D, et al (2007) Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 37:145–52PubMedCrossRefGoogle Scholar
  25. 25.
    Glasziou P, Irwig L, Deeks JJ (2008) When should a new test become the current reference standard? Ann Intern Med 149(11):816–22PubMedCrossRefGoogle Scholar
  26. 26.
    Twerenbold R, Reichlin T, Reiter M, et al (2010) Economic benefit of copeptin for rapid rule out of acute myocardial infarction. Congress of the European Society of Cardiology 2010. Stockholm, SwedenGoogle Scholar

Copyright information

© Société française de médecine d'urgence and Springer-Verlag France 2013

Authors and Affiliations

  • S. Ledochowski
    • 1
  • J.-M. Fayet
    • 2
  • D. Collin-Chavagnac
    • 3
  • E. Bonnefoy-Cudraz
    • 4
  1. 1.Pôle des urgences, service d’accueil des urgences et service d’anesthésie-réanimation, chemin du Grand-RevoyetHospices civils de Lyon, Centre hospitalo-universitaire Lyon SudLyon cedex 03France
  2. 2.Pôle des urgences, service d’accueil des urgences, chemin du Grand-RevoyetHospices civils de Lyon, Centre hospitalo-universitaire Lyon SudLyon cedex 03France
  3. 3.Pôle de biologie et d’anatomie pathologique, service de biochimie et biologie moléculaire Sud, chemin du Grand-RevoyetHospices civils de Lyon, Centre hospitalo-universitaire Lyon SudLyon cedex 03France
  4. 4.Centre d’investigation clinique, hôpital cardiovasculaire et pneumologiqueHospices civils de Lyon, UMR 5558, Université Lyon-ILyon cedex 03France

Personalised recommendations